A Safety and Efficacy Study of a Single Center, Open-label, Single Arm About the Gene Correction of HBB in Patient-specific iHSCs Using CRISPR/Cas9 That Intervent Subjests With β-thalassemia Mutations
Latest Information Update: 06 Jan 2021
At a glance
- Drugs CRISPR/Cas9 modified human haematopoietic stem cell therapy-Allife Medical Science and Technology (Primary)
- Indications Beta-thalassaemia
- Focus Adverse reactions
- Sponsors Allife Medical Science and Technology
Most Recent Events
- 13 Nov 2018 New trial record